News
Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators ...
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results